Mutations associated with progression confer adverse risk in newly diagnosed FL. Kaplan-Meier curves displaying univariate frontline PFS in patients with FL by (A) CREBBP, (B) TP53, (C) SOCS1, and (D) MAP signature status. (E) Forest plot of multivariate model for frontline PFS incorporating MAP signature status, traditional FLIPI group, and patient Eastern Cooperative Oncology Group performance status; significant P values are marked with asterisks.